Oncology was Dr Reddys Laboratories’s largest segment in fiscal 2026, bringing in $63.13B of $286.13B (22%).
| Segments [axis] | FY 2021 | FY 2025 | FY 2026 |
|---|---|---|---|
| Oncology | $85.80B | $63.13B | |
| Central Nervous System | $43.35B | $61.29B | |
| Gastrointestinal | $25.32B | $27.62B | |
| Pain Management | $27.55B | $30.11B | |
| Others | $6.78B | $8.56B | |
| Cardiovascular | $18.55B | $21.20B | |
| Respiratory | $17.03B | $21.87B | |
| Anti-Infective | $12.77B | $13.20B | |
| Hematology | $8.63B | $8.35B | |
| Nutraceutical | $9.13B | $8.02B | |
| Diabetology | $7.45B | $12.43B | |
| Dermatology | $6.43B | $8.13B | |
| Anti Infective One | $1.68B | $1.74B | |
| Genitourinary | $416.00M | $475.00M | |
| Total | $270.88B | $286.13B |
Dr Reddys Laboratories brought in $286.13B from its 14 segments in fiscal 2026, the year ended March 31, 2026. That is less than the $335.93B it reports by geography, so these segments do not cover all of its revenue. Oncology was the largest at $63.13B (22.1%), ahead of Central Nervous System at $61.29B (21.4%) and Pain Management at $30.11B (10.5%). The other 11 segments brought in $131.59B combined.
Compared with fiscal 2025, Diabetology grew fastest, up 66.8% to $12.43B, while Oncology fell the most, down 26.4% to $63.13B.
Others was Dr Reddys Laboratories’s largest region in fiscal 2026, bringing in $118.72B of $335.93B (35%).
| Geography | FY 2016 | FY 2018 | FY 2019 | FY 2022 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|
| United States | $149.35B | $117.89B | ||||
| Others | $94.40B | $118.72B | ||||
| Oncology | — | — | ||||
| India | $55.83B | $64.54B | ||||
| Russia | $25.96B | $34.79B | ||||
| Total | $325.54B | $335.93B |
Dr Reddys Laboratories brought in $335.93B from its four regions in fiscal 2026, the year ended March 31, 2026. That was up 3.2% from $325.54B in fiscal 2025. Others was the largest at $118.72B (35.3%), ahead of United States at $117.89B (35.1%) and India at $64.54B (19.2%). The remaining region, Russia, brought in $34.79B.
Compared with fiscal 2025, Russia grew fastest, up 34.0% to $34.79B, while United States fell the most, down 21.1% to $117.89B.
Dr Reddys Laboratories (RDY) reports its revenue by segments [axis] and by geography. In fiscal 2026, Oncology was its largest segment, bringing in $63.13B (22.1% of the total), followed by Central Nervous System at $61.29B (21.4%).
Oncology was Dr Reddys Laboratories' largest segment in fiscal 2026, bringing in $63.13B, or 22.1% of the $286.13B total across its 14 segments.
Others was Dr Reddys Laboratories' largest region in fiscal 2026, bringing in $118.72B, or 35.3% of the $335.93B total across its four regions.
Among Dr Reddys Laboratories' segments that make up at least 2% of revenue, Diabetology grew fastest in fiscal 2026, up 66.8% from $7.45B to $12.43B.
Every figure comes from Dr Reddys Laboratories' annual financial filings, as reported. Each line keeps the name Dr Reddys Laboratories gives it, and years follow its fiscal calendar.
Dr Reddys Laboratories' revenue by segments [axis] goes back to fiscal 2021, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.